Loading...
•
Jun 30, 2020
CRISPR Therapeutics Q2 2020 Earnings Report
CRISPR Therapeutics reported financial results for the second quarter ended June 30, 2020.
Key Takeaways
CRISPR Therapeutics reported a net loss of $79.7 million for the second quarter of 2020, with total collaboration revenue of less than $0.1 million. Cash and cash equivalents were $945.1 million as of June 30, 2020.
Dosing re-initiated in clinical trials of CTX001 for patients with severe hemoglobinopathies.
CTX001 received orphan drug designation from the U.S. FDA for sickle cell disease (SCD).
Expanded regenerative medicine portfolio through a collaboration with University Health Network (UHN), gaining access to hepatocytes.
Company expects to report data from its CTX001 program targeting hemoglobinopathies and its CTX110 program later this year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...